TL;DR: Experience the internet ad-free forever with this lifetime subscription to AdGuard Family Plan, on sale now for just $39.99 (reg. $169.99).
We’ve all been there — minding our own…
Blog
-
Prince Andrew’s scandals threaten to undo William, Kate’s royal progress
Prince Andrew’s controversies overshadow William, Kate’s royal work Prince Andrew’s ongoing scandals are casting a shadow over the positive efforts of Prince William and Kate Middleton.
According to Radar…
Continue Reading
-
expert reaction to conference abstract on the DYNAMIC-III study on ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer
A conference abstract presented at the European Society for Medical Oncology (ESMO) 2025 meeting looks at…
Continue Reading
-
Kering to sell beauty unit to L'Oreal for $4.66 billion – Reuters
- Kering to sell beauty unit to L’Oreal for $4.66 billion Reuters
- Exclusive | Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L’Oréal wsj.com
- Kering to sell beauty unit to L’Oreal for $4.66 billion By Reuters Investing.com
- Gucci owner Kering is said to be nearing deal to sell Beauty unit to L’Oréal Seeking Alpha
- Kering and L’Oréal forge an alliance in beauty and wellness GlobeNewswire
Continue Reading
-
OnePlus 15: Global model stars in early benchmark before rumoured November release
To recap, the Snapdragon 8 Elite helped the OnePlus 13 average 3,087 and 9,369 in Geekbench 6’s single-core and multi-core benchmarks, respectively. For context, these scores are slightly higher than the median of Snapdragon 8 Elite-powered…
Continue Reading
-
How Callum Turner and Dua Lipa Make Long Distance Work
If you need some reassurance that love is real, let me point you towards hot and famous fiancés Dua Lipa and Callum Turner. If seeing them dance under the…
Continue Reading
-
ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus Placebo + Abiraterone in Patients with PTEN-deficient De Novo Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281 – UroToday
- ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus Placebo + Abiraterone in Patients with PTEN-deficient De Novo Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281 UroToday
- Truqap Extends Radiographic Progression-Free Survival in Some With Prostate Cancer CUREtoday.com
- Capivasertib prolongs rPFS in PTEN-deficient hormone-sensitive prostate cancer Urology Times
Continue Reading
